Inactive Instrument

Highlights Aradigm Corporation OTC Bulletin Board

Equities

ARDM

US0385053014

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2020	Aradigm Corporation Went Out of Business	CI
2020	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	20-03-30	CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	20-02-20	CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	19-10-30	CI
Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	19-10-21	CI
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019	19-02-22	CI
Aradigm Corporation Announces Detailed Third Party Evaluation Results for Apulmiq/Linhaliq	19-01-16	CI
Aradigm Announces Results of Third Party Verification for Apulmiq	18-12-20	CI
Aradigm Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-15	CI
Aradigm Corporation Announces Consolidated Earnings for the Second Quarter and Six Months Ended June 30, 2018	18-08-14	CI
Aradigm Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-15	CI
Aradigm Corporation Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-23	CI
Aradigm Corporation Submits Marketing Authorisation Application to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis	18-03-09	CI
Aradigm Corporation Receives Complete Response Letter from the FDA for Linhaliq NDA	18-01-29	CI
Aradigm Corporation Reports Results of FDA Advisory Committee Meeting on Linhaliq	18-01-11	CI
Aradigm Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-02	CI
Aradigm Corporation Announces U.S. Food and Drug Administration Acceptance of NDA for Linhaliq with Priority Review Status	17-09-25	CI
Aradigm Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-10	CI
Aradigm Corporation Submits New Drug Application to the U.S. Food and Drug Administration for Linhaliq	17-07-27	CI
Aradigm Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-15	CI
Aradigm Corporation Announces Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-03-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aradigm Corporation OTC Bulletin Board

Equities

ARDM

US0385053014

Highlights

Filters